PR Newswire Clinical TrialsOriginal article
Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer
Data Readoutpositiveendocrine therapyPositive
AI Analysis
Summary
Caris Life Sciences announced publication of a collaborative study with ECOG-ACRIN and NRG Oncology in Cancer Research Communications demonstrating a multimodal AI approach to predict late distant recurrence risk in HR+ early breast cancer. The findings may inform extended endocrine therapy treatment decisions.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Study demonstrates multimodal AI approach to predict late distant recurrence risk in HR+ early breast cancer, with findings published in Cancer Research Communications
Importance:5/10
Sentiment:
0.60
AIbreast cancerearly stageHR+ positiverecurrence predictionendocrine therapypublication
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 6, 2026 12:30 PM